Corvus Pharmaceuticals Stock Forecast, Price & News

+0.85 (+15.98 %)
(As of 09/20/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume74.28 million shs
Average Volume2.34 million shs
Market Capitalization$261.74 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive CRVS News and Ratings via Email

Sign-up to receive the latest news and ratings for Corvus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Corvus Pharmaceuticals logo

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of oncology therapies. The firm focuses on disabling cancer's ability to subvert immune attack by inhibiting adenosine in the tumor microenvironment and by blocking its production by tumors. Its product pipeline includes B Cell Activator, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson and Joseph J. Buggy on January 27, 2014 and is headquartered in Burlingame, CA.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.13 out of 5 stars

Medical Sector

425th out of 1,352 stocks

Pharmaceutical Preparations Industry

209th out of 665 stocks

Analyst Opinion: 1.3Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Corvus Pharmaceuticals (NASDAQ:CRVS) Frequently Asked Questions

Is Corvus Pharmaceuticals a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corvus Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Corvus Pharmaceuticals stock.
View analyst ratings for Corvus Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Corvus Pharmaceuticals?

Wall Street analysts have given Corvus Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Corvus Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Corvus Pharmaceuticals?

Corvus Pharmaceuticals saw a decline in short interest in the month of August. As of August 13th, there was short interest totaling 975,800 shares, a decline of 22.6% from the July 29th total of 1,260,000 shares. Based on an average trading volume of 220,500 shares, the days-to-cover ratio is presently 4.4 days. Approximately 3.5% of the shares of the company are sold short.
View Corvus Pharmaceuticals' Short Interest

When is Corvus Pharmaceuticals' next earnings date?

Corvus Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Corvus Pharmaceuticals

How were Corvus Pharmaceuticals' earnings last quarter?

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) released its quarterly earnings results on Sunday, August, 1st. The company reported ($0.28) EPS for the quarter, beating analysts' consensus estimates of ($0.32) by $0.04.
View Corvus Pharmaceuticals' earnings history

How has Corvus Pharmaceuticals' stock price been impacted by COVID-19 (Coronavirus)?

Corvus Pharmaceuticals' stock was trading at $2.71 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CRVS shares have increased by 127.7% and is now trading at $6.17.
View which stocks have been most impacted by COVID-19

What price target have analysts set for CRVS?

3 equities research analysts have issued 12-month price objectives for Corvus Pharmaceuticals' shares. Their forecasts range from $3.50 to $6.00. On average, they expect Corvus Pharmaceuticals' share price to reach $4.83 in the next year. This suggests that the stock has a possible downside of 21.7%.
View analysts' price targets for Corvus Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Corvus Pharmaceuticals' key executives?

Corvus Pharmaceuticals' management team includes the following people:
  • Richard A. Miller, Chairman, President & Chief Executive Officer
  • Leiv Lea, Chief Financial Officer
  • Mehrdad Mobasher, Chief Medical Officer & Senior Vice President
  • Joseph J. Buggy, Executive Vice President-Discovery Research
  • William B. Jones, Senior Vice President-Pharmaceutical Development

What is Richard A. Miller, MD's approval rating as Corvus Pharmaceuticals' CEO?

4 employees have rated Corvus Pharmaceuticals CEO Richard A. Miller, MD on Richard A. Miller, MD has an approval rating of 100% among Corvus Pharmaceuticals' employees. This puts Richard A. Miller, MD in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Corvus Pharmaceuticals' key competitors?

What other stocks do shareholders of Corvus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Corvus Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Dynavax Technologies (DVAX), Vaxart (VXRT), Zosano Pharma (ZSAN), SCYNEXIS (SCYX), Miragen Therapeutics (MGEN), Aldeyra Therapeutics (ALDX) and Bionano Genomics (BNGO).

When did Corvus Pharmaceuticals IPO?

(CRVS) raised $75 million in an initial public offering (IPO) on Wednesday, March 23rd 2016. The company issued 4,700,000 shares at $15.00-$17.00 per share. Credit Suisse and Cowen and Company served as the underwriters for the IPO and Guggenheim Securities, Cantor Fitzgerald and BTIG were co-managers.

What is Corvus Pharmaceuticals' stock symbol?

Corvus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRVS."

Who are Corvus Pharmaceuticals' major shareholders?

Corvus Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include BVF Inc. IL (8.67%), Vanguard Group Inc. (2.61%), CHI Advisors LLC (1.70%), Renaissance Technologies LLC (1.55%), Dimensional Fund Advisors LP (0.93%) and Telemetry Investments L.L.C. (0.62%). Company insiders that own Corvus Pharmaceuticals stock include Holdings A/S Novo, Orbimed Advisors Llc and Richard A Md Miller.
View institutional ownership trends for Corvus Pharmaceuticals

Which institutional investors are selling Corvus Pharmaceuticals stock?

CRVS stock was sold by a variety of institutional investors in the last quarter, including Laurion Capital Management LP, Citadel Advisors LLC, Algert Global LLC, Dimensional Fund Advisors LP, Renaissance Technologies LLC, and Goldman Sachs Group Inc..
View insider buying and selling activity for Corvus Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Corvus Pharmaceuticals stock?

CRVS stock was bought by a variety of institutional investors in the last quarter, including BVF Inc. IL, Vanguard Group Inc., Geode Capital Management LLC, CHI Advisors LLC, Millennium Management LLC, State Street Corp, Northern Trust Corp, and Telemetry Investments L.L.C.. Company insiders that have bought Corvus Pharmaceuticals stock in the last two years include Orbimed Advisors Llc, and Richard A Md Miller.
View insider buying and selling activity for Corvus Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Corvus Pharmaceuticals?

Shares of CRVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Corvus Pharmaceuticals' stock price today?

One share of CRVS stock can currently be purchased for approximately $6.17.

How much money does Corvus Pharmaceuticals make?

Corvus Pharmaceuticals has a market capitalization of $261.74 million. The company earns $-5,990,000.00 in net income (profit) each year or ($1.47) on an earnings per share basis.

How many employees does Corvus Pharmaceuticals have?

Corvus Pharmaceuticals employs 42 workers across the globe.

What is Corvus Pharmaceuticals' official website?

The official website for Corvus Pharmaceuticals is

Where are Corvus Pharmaceuticals' headquarters?

Corvus Pharmaceuticals is headquartered at 863 Mitten Road Suite102, BURLINGAME CA, 94010.

How can I contact Corvus Pharmaceuticals?

Corvus Pharmaceuticals' mailing address is 863 Mitten Road Suite102, BURLINGAME CA, 94010. The company can be reached via phone at (650) 900-4520 or via email at [email protected].

This page was last updated on 9/20/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.